RxDoctor Payments Data

Tatyana Tsipursky, MD

Psychiatry · Brooklyn, NYNPI 1275506974

Payments from drug & device makers

$12,506in general payments, 2019–2025

Across 529 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • Lundbeck LLC$2K
  • Sunovion Pharmaceuticals Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • plus $4K from 13 others

What the payments were for

  • Food & beverage$12,33499%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,506 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$619,898
Medicare patients
612
Services billed
6,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole631$1,046,145
VraylarCariprazine Hcl269$375,699
CaplytaLumateperone Tosylate163$270,486
TrintellixVortioxetine Hydrobromide468$233,040
NamzaricMemantine Hcl/Donepezil Hcl397$232,528
IngrezzaValbenazine Tosylate25$187,430
AuvelityDextromethorphan Hbr/Bupropion130$99,260
Wellbutrin XlBupropion Hcl37$91,766
LybalviOlanzapine/Samidorphan Malate34$54,098
ExelonRivastigmine52$39,918
NuedextaDextromethorphan Hbr/Quinidine32$39,575
UbrelvyUbrogepant26$32,245
LexaproEscitalopram Oxalate69$30,763
LatudaLurasidone Hcl23$30,057
Memantine Hcl ErMemantine Hcl464$27,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$2,476$1,072,957643 claims
AbbVieVraylar, Namzaric, Ubrelvy, Lexapro, Fetzima$1,512$677,903775 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,149$270,486163 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$254$233,040468 claims
Neurocrine Biosciences, Inc.Ingrezza$682$187,43025 claims
Axsome Therapeutics, Inc.Auvelity$709$99,260130 claims
Alkermes, Inc.Lybalvi$1,104$54,09834 claims
Sunovion Pharmaceuticals Inc.Latuda$1,166$30,05723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →